Abstract
Virtually all individuals with Down syndrome (DS) will develop Alzheimer's disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers have characterized AD pathology in cohorts of late-onset AD (LOAD) and autosomal-dominant AD (ADAD). Few studies have evaluated such biomarkers in adults with DS. CSF concentrations of amyloid beta (Aβ)40, Aβ42, tau, phospho-tau181 (p-tau), neurofilament light chain (NfL), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase-3-like protein 1 (YKL-40), alpha synuclein (αSyn), neurogranin (Ng), synaptosomal-associated protein 25 (SNAP-25), and visinin-like protein 1 (VILIP-1) were assessed in CSF from 44 adults with DS from the Alzheimer's Biomarker Consortium-Down Syndrome study. Biomarker levels were evaluated by cognitive status, age, and apolipoprotein E gene (APOE) ε4 carrier status. Biomarker abnormalities indicative of amyloid deposition, tauopathy, neurodegeneration, synaptic dysfunction, and neuroinflammation were associated with increased cognitive impairment. Age and APOE ε4 status influenced some biomarkers. The profile of many established and emerging CSF biomarkers of AD in a cohort of adults with DS was similar to that reported in LOAD and ADAD, wh...Continue Reading
References
Aug 13, 1993·Science·E H CorderM A Pericak-Vance
Apr 1, 1997·Journal of Intellectual Disability Research : JIDR·E H AylwardA Dalton
Jul 18, 2000·Journal of Intellectual Disability Research : JIDR·D B Burt, E H Aylward
Aug 2, 2003·Annals of Neurology·Pau PastorAlison M Goate
Feb 27, 2010·Annals of Neurology·John C MorrisMark A Mintun
Nov 3, 2010·Biological Psychiatry·Rebecca Craig-SchapiroDavid M Holtzman
Aug 9, 2011·Annals of Neurology·Rawan TarawnehDavid M Holtzman
Apr 23, 2013·Journal of Alzheimer's Disease : JAD·Ane KorffUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Mar 22, 2014·PloS One·Justyna A DobrowolskaRandall J Bateman
Jun 15, 2014·Neurology·Davis C RymanUNKNOWN Dominantly Inherited Alzheimer Network
Jul 6, 2014·Neuro-degenerative Diseases·Erik PorteliusNiklas Mattsson
Dec 3, 2014·Brain Research·Andrew O KoobEliezer Masliah
Jul 7, 2015·JAMA Neurology·Courtney L SutphenAnne M Fagan
Sep 15, 2015·JAMA Neurology·Maartje I KesterAnne M Fagan
Dec 2, 2015·Molecular Psychiatry·J I VélezM Arcos-Burgos
Jan 13, 2016·Acta Neuropathologica·Laura PiccioCarlos Cruchaga
Mar 29, 2016·JAMA Neurology·Rawan TarawnehDavid M Holtzman
Aug 19, 2016·EMBO Molecular Medicine·Niklas MattssonUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Dec 16, 2016·Science Translational Medicine·Marc Suárez-CalvetUNKNOWN Dominantly Inherited Alzheimer Network
Dec 18, 2016·Clinical Chemistry·Daniel L CrimminsJack H Ladenson
Apr 18, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Alain D DekkerPeter P De Deyn
Jul 25, 2017·Neurology and Therapy·Ni-Chung LeeWuh-Liang Hwu
Dec 6, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Jennifer G GoldmanUn Jung Kang
Mar 28, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Courtney L SutphenUNKNOWN ADNI
Aug 15, 2018·Neurobiology of Aging·Niklas MattssonOskar Hansson
Aug 26, 2018·Neuroscience Letters·Shanshan WangUNKNOWN for Alzheimer’s Disease Neuroimaging Initiative
Sep 3, 2018·Lancet Neurology·Juan ForteaAlberto Lleó
Sep 16, 2018·Neurology·Eric McDadeUNKNOWN Dominantly Inherited Alzheimer Network
Nov 28, 2018·Acta Neuropathologica Communications·Daniel TwohigUNKNOWN Dominantly Inherited Alzheimer Network (DIAN)
Nov 30, 2018·Acta Neuropathologica·José Luis MolinuevoKaj Blennow
Feb 9, 2019·Nature Reviews. Neurology·Ira T Lott, Elizabeth Head
Mar 9, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Suzanne E SchindlerUNKNOWN Dominantly Inherited Alzheimer Network
Nov 12, 2019·EMBO Molecular Medicine·Sebastian PalmqvistOskar Hansson